Due to lack of physiological expression in normal tissue of common metastatic sites of prostate cancer, and its advantages compared to conventional imaging, PSMA positron emission tomography (PET) imaging has become a major diagnostic tool in mCRPC patients [7,8,9] After the great success of PSMA based imaging, the application of PSMA targeted therapies with alpha- or beta-emitters was only a matter of time. The gene discussed is FOLH1; the disease is prostate carcinoma.